Table I.
CAR-T products approved to treat hematological malignancies.
| Drug | Target | Targeted diseases | Time of approval | Listing location | Guide price |
|---|---|---|---|---|---|
| Kymriah | CD19 | B-ALL; DLBCL | August 2017 | USA | 475,000 USD |
| Yescarta | CD19 | DLBCL; RRFL | October 2017 | USA | 373,000 USD |
| Tecartus | CD19 | R/R MCL | July 2020 | USA | 373,000 USD |
| Breyanzi | CD19 | DLBCL | February 2021 | USA | 410,000 USD |
| Abecma | BCMA | R/R MM | March 2021 | USA | 437,000 USD |
| Relma-cel | CD19 | DLBCL | September 2021 | China | 12,00,000 RMB |
| Carvykti | BCMA | R/R MM | February 2022 | USA | 460,000 USD |
The guide price is for the full treatment for one patient. B-ALL, B-cell acute lymphoblastic leukemia; DLBCL, Diffuse large B-cell lymphoma; R/R FL, relapsed or refractory follicular lymphoma; R/R MCL, relapsed or refractory mantle cell lymphoma; R/R MM, relapsed or refractory multiple myeloma.